表观遗传甲基化（Epigenetic methylation）.doc

表观遗传甲基化（Epigenetic methylation） TCF21 and PCDH17 methylation A new biomarker combination for simultaneous detection of urologic cancer Cancer epigenetics group; genetic cancer group; research center of Portugal Oncology Institute; Department of genetics, pathology and oncology, Department of Urology; Portugal Porto College; Oporto University of science and pathology of Portugals Laboratory of molecular immunology and Biomedical Science Research Institute and cancer prevention (Cancer Research Institute) Abel Salazar; Norway radiu m hospital; the Cancer Center Hospital of Norway University of Oslo biomedical University of Oslo. Keyword: urinary tract tumor; early detection; DNA methylation; urine detection If early detection, the urinary systems three largest tumor can be surgically cured. We aimed to validate the new DNA methylation biomarkers associated with these three urological tumors and thus become potential non-invasive tests. After evaluating the drug cell and tissue samples, we created a set of target genes for gene expression, and 2 target genes were used for further studies. The methylation levels of these genes were quantified in 12 cancer cell lines and 318 clinical pathological samples. The sensitivity of PCDH17 and TCF21 methylation levels to bladder cancer, renal cell carcinoma and prostate cancer were 92%, 67% and 96% respectively. Methylation levels vary considerably in these cancer individuals, showing a sensitivity of 83% and a specificity of 100%. Introduction Genitourinary cancers are mainly prostate cancer, bladder cancer, and renal tumors, including significant morbidity and mortality in heterogeneous malignancies. Overall, it is estimated that prostate, bladder and kidney tumors worldwide diagnosed in 2008 are 1571483 new cases, representing second malignant tumor systems in humans, second only to lung cancer. In 2010, in the United States, urinary cancer patients constituted the most common and most lethal tumor system of malignant tumors,